<DOC>
	<DOCNO>NCT00001041</DOCNO>
	<brief_summary>To evaluate safety rgp120/HIV-1MN vaccine HIV-1 infect pregnant woman CD4 count &gt; = 400 cells/mm3 . To evaluate immunogenicity vaccine pregnant woman passive acquisition vaccine-specific antibody infant . To evaluate induction augmentation rgp120/HIV-1MN vaccine mucosal immune response gastrointestinal reproductive tract pregnancy . To isolate genetically characterize HIV-1 present cervicovaginal fluid specimen pregnant woman compare present peripheral blood mononuclear cell infected infant . Evidence suggest advanced stage disease high plasma viremia associate increased transmission HIV-1 fetus . Slowing progression disease , reduce titer virus plasma , increase titer epitope-specific antibody potentially attainable goal active immunization mother pregnancy .</brief_summary>
	<brief_title>Active Immunization HIV-1 Infected , Pregnant Women With CD4 Lymphocyte Counts &gt; = 400/mm3 : A Phase I Study Safety Immunogenicity MN rgp120/HIV-1 Vaccine ( NOTE : Some Patients Receive Placebo )</brief_title>
	<detailed_description>Evidence suggest advanced stage disease high plasma viremia associate increased transmission HIV-1 fetus . Slowing progression disease , reduce titer virus plasma , increase titer epitope-specific antibody potentially attainable goal active immunization mother pregnancy . Pregnant woman randomize receive initial injection MN rgp120 vaccine alum placebo week 16 week 24 gestation , follow monthly booster injection conclude end pregnancy , total five injection . Patients may optional booster immunization ( vaccine placebo ) 3 , 6 , 9 , 12 month delivery . Mothers infants follow 18 month delivery . Per 06/94 addendum , patient contact twice per year least 5 year check health status patient child . PER 12/21/94 ADDENDUM , post-partum immunization discontinue .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : AZT . Acyclovir . Patients must : HIV1 infection . CD4 count &gt; = 400 cells/mm3 . No AIDSdefining illness systemic manifestation relate HIV ( generalize lymphadenopathy ) . HIV p24 &lt; 30 pg/ml . Proven pregnancy 16th 24th week gestation study entry , special obstetrical risk . Concurrent AZT therapy permit . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Known hypersensitivity component vaccine . Evidence fetal abnormality ultrasound . Evidence maternal risk factor include insulindependent diabetes , moderate severe hypertension , repeat fetal wastage ( &gt; 3 ) , Rhsensitization blood group alloimmunization , severe renal disease , previous infant malformation factor obstetrically judge constitute special risk spontaneous abortion premature birth . Active syphilis . Hepatitis B surface antigen positive . Concurrent Medication : Excluded : Antiretroviral immunomodulating agent AZT pregnancy . Prior Medication : Excluded : Antiretroviral immunomodulating agent AZT within 90 day prior study entry . Current use illicit drug know chronic alcohol use .</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Pregnancy Complications , Infectious</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Therapeutic Vaccine</keyword>
</DOC>